Adagene

ADAG · NASDAQ

$2.50+$0.21 (+9.17%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.29

Latest news

Press releaseOct 14, 8:00 AM ETGlobe Newswire
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
Press releaseSep 22, 8:00 AM ETGlobe Newswire
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Press releaseSep 10, 8:00 AM ETGlobe Newswire
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Press releaseSep 9, 8:00 AM ETGlobe Newswire
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Press releaseAug 20, 8:00 AM ETGlobe Newswire
Adagene to Participate in Three Upcoming Investor Conferences
Press releaseAug 12, 7:30 AM ETGlobe Newswire
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
NewsMay 21, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMay 12, 8:30 AM ETGlobe Newswire
Adagene to Participate in Two Upcoming Investor Conferences
Press releaseApr 17, 4:01 PM ETGlobe Newswire
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
Press releaseApr 14, 7:00 AM ETGlobe Newswire
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
Press releaseApr 2, 7:01 AM ETGlobe Newswire
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
NewsMar 11, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsNov 11, 12:09 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsAug 14, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsSep 16, 6:07 AM ETAvi Kapoor
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Press releaseSep 16, 3:01 AM ETGlobe Newswire
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Press releaseJul 25, 4:05 PM ETGlobe Newswire
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Adagene to Participate in Three Upcoming Investor Conferences

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

12 Health Care Stocks Moving In Thursday's After-Market Session

Adagene to Participate in Two Upcoming Investor Conferences

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update